LDL Cholesterol

If you remember one number from a cholesterol panel, it is almost certainly this one. LDL is the "bad cholesterol," the figure doctors treat, the target of an entire class of medications. For once, the popular reputation is mostly deserved: of everything on a lipid panel, LDL has the deepest and most consistent evidence behind it.

What that evidence actually says is striking in its simplicity. LDL cholesterol is not just associated with heart disease; it causes it, and the relationship has no comfortable threshold. Across the whole range, lower is better, and the benefit compounds the longer your LDL stays low. A lifetime spent at a modestly lower level prevents far more disease than a late-life scramble to bring a high number down.

So the case for paying attention is settled. What is worth knowing is what the single number leaves out: LDL cholesterol measures the cargo, the weight of cholesterol being carried, not the traffic, the number of particles carrying it. Most of the time the two track together, and when they do not, the number can quietly mislead.

LDL particles are what remain after the body has used up the triglycerides in larger VLDL particles. Stripped of most of their fat, these cholesterol-rich particles circulate and deliver cholesterol to cells, and they are normally cleared from the blood by LDL receptors in the liver. When those receptors are few or faulty, as in the genetic condition familial hypercholesterolemia, LDL climbs and heart disease arrives early, which was one of the first clues that LDL is causal rather than incidental.

The damage itself is a matter of retention. LDL particles penetrate the inner lining of the artery, become trapped in the wall, oxidize, and trigger the immune response that builds an atherosclerotic plaque. Genetic studies make the causal chain unambiguous: people who inherit lifelong lower LDL have proportionally less coronary disease, in a clean dose-and-duration relationship ^[1]. The scientific consensus is now explicit that LDL is a cause of atherosclerotic cardiovascular disease, not merely a marker of it ^[2].

One practical wrinkle sits inside the number. On most panels, LDL cholesterol is not measured directly; it is calculated from your total cholesterol, HDL, and triglycerides. That estimate works well in the middle of the range but loses accuracy when triglycerides are high or when LDL is very low, which is exactly where precision matters most ^[3]. It is worth knowing that your LDL number is often an estimate, not a direct count.

The strength of the LDL evidence is its consistency. The relationship with cardiovascular risk is log-linear and without a clear floor, and what matters most is cumulative exposure, the area under the curve of LDL multiplied by years ^[1]. This is why starting lower and staying lower beats any late correction, and why guidelines set progressively lower targets for people at higher risk rather than a single universal cutoff ^[4].

Where LDL cholesterol falls short is in that cargo-versus-count gap. Because risk tracks the number of atherogenic particles, and because each particle carries one ApoB, ApoB is a more direct measure of the thing that actually does damage. In the roughly one in four people whose cholesterol cargo and particle count diverge, often those with high triglycerides, insulin resistance, or many small dense LDL particles, the particle count predicts risk better than the cholesterol number does ^[5]. None of this demotes LDL. It refines it: LDL tells you the established, actionable story, and ApoB sharpens the picture when the two disagree.

A final point of reassurance runs the other way. Because the popular framing is "bad cholesterol," people sometimes worry that a low LDL is dangerous. For levels reached through healthy living or genetics, it is not; lower LDL is associated with less disease across the range, and the apparent risks of very low values are largely explained by underlying illness lowering the number, not the other way around.